Our study revealed the distinct impacts of NAC or NAPC on tumor immune microenvironment and identified key immune cell subsets by which PD-1 blockade enhances the antitumor immune response to chemotherapy, providing new insights for improving the efficiency of immunotherapy and chemotherapy in NSCLC. This evidence concerns the gene PDCD1 and neoplasm.